Biogen splits R&D division ahead of key decision on Alzheimer's drug

France Nouvelles Nouvelles

Biogen splits R&D division ahead of key decision on Alzheimer's drug
France Dernières Nouvelles,France Actualités
  • 📰 Reuters
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 97%

Biogen Inc said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.

said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.

The company named interim R&D chief Priya Singhal as executive vice president, head of development following the separation. Singhal will also serve as the interim head of research till the company completes its search for a new chief for that division. Both Singhal and the new research head will report to Chief Executive Officer Christopher Viehbacher, the former Sanofi SA

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Reuters /  🏆 2. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Biogen separates research and development into two functionsBiogen separates research and development into two functionsBiogen Inc. said Thursday that it separated research and development into two functions that report directly to new CEO Christopher Viehbacher. Priya...
Lire la suite »

FDA set to make decision on experimental Alzheimer's drug this weekFDA set to make decision on experimental Alzheimer's drug this weekThe Food and Drug Administration is expected to decide by Friday whether to grant accelerated approval for Eisai and Biogen's experimental Alzheimer's drug, lecanemab.
Lire la suite »

Hotflash inc: We joke about menopause, but the health risks aren't funnyHotflash inc: We joke about menopause, but the health risks aren't funny.hotflashinc: We joke about menopause, but the health risks aren't funny – via healthing_ca healthing healthnews womenshealth
Lire la suite »

LeRoy Cavazos-Reyna returns to San Antonio with Localism, Inc.LeRoy Cavazos-Reyna returns to San Antonio with Localism, Inc.LeRoy Cavazos-Reyna has left the U.S. Hispanic Chamber of Commerce, but will remain focused on minority-owned business development, now in San Antonio.
Lire la suite »

How chat bots can actually detect Alzheimer’s diseaseHow chat bots can actually detect Alzheimer’s diseaseBots “could be a simple, accessible and adequately sensitive tool for community-based testing,” researchers say.
Lire la suite »

UT researchers fight Alzheimer's with fitness gadgetsUT researchers fight Alzheimer's with fitness gadgetsMedical researchers in Austin are using commercially available technology to determine who is at risk of longer-term cognitive dysfunction such as Alzheimer's disease.
Lire la suite »



Render Time: 2025-03-06 14:09:37